CN117858722A - 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂 - Google Patents
用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂 Download PDFInfo
- Publication number
- CN117858722A CN117858722A CN202280054611.7A CN202280054611A CN117858722A CN 117858722 A CN117858722 A CN 117858722A CN 202280054611 A CN202280054611 A CN 202280054611A CN 117858722 A CN117858722 A CN 117858722A
- Authority
- CN
- China
- Prior art keywords
- antibody
- formulation
- arginine hydrochloride
- polysorbate
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 20
- 108090001005 Interleukin-6 Proteins 0.000 title claims abstract description 18
- 201000010099 disease Diseases 0.000 title claims abstract description 15
- 239000012669 liquid formulation Substances 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 175
- 238000009472 formulation Methods 0.000 claims abstract description 170
- 238000010254 subcutaneous injection Methods 0.000 claims abstract description 10
- 239000007929 subcutaneous injection Substances 0.000 claims abstract description 10
- 239000000872 buffer Substances 0.000 claims description 71
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 66
- 229960003589 arginine hydrochloride Drugs 0.000 claims description 66
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 58
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 58
- 229920000053 polysorbate 80 Polymers 0.000 claims description 58
- 229940068968 polysorbate 80 Drugs 0.000 claims description 58
- 239000003381 stabilizer Substances 0.000 claims description 56
- 229930006000 Sucrose Natural products 0.000 claims description 46
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 46
- 239000005720 sucrose Substances 0.000 claims description 46
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 43
- 229930182817 methionine Natural products 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 39
- 239000008215 water for injection Substances 0.000 claims description 38
- 239000000243 solution Substances 0.000 claims description 31
- 239000004094 surface-active agent Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- 239000007853 buffer solution Substances 0.000 claims description 16
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 12
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 12
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 12
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims description 10
- 229940074409 trehalose dihydrate Drugs 0.000 claims description 10
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 9
- 208000005024 Castleman disease Diseases 0.000 claims description 6
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 6
- 206010036030 Polyarthritis Diseases 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 6
- 230000009885 systemic effect Effects 0.000 claims description 6
- 206010043207 temporal arteritis Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010050685 Cytokine storm Diseases 0.000 claims description 3
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010065159 Polychondritis Diseases 0.000 claims description 3
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 208000024340 acute graft versus host disease Diseases 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 229940071643 prefilled syringe Drugs 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 2
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 11
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 7
- 238000004220 aggregation Methods 0.000 abstract description 3
- 230000002776 aggregation Effects 0.000 abstract description 3
- 230000015556 catabolic process Effects 0.000 abstract description 3
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 description 36
- 108020003175 receptors Proteins 0.000 description 36
- 150000002411 histidines Chemical class 0.000 description 29
- 150000003839 salts Chemical class 0.000 description 26
- 229940100601 interleukin-6 Drugs 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 14
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 14
- 229960002885 histidine Drugs 0.000 description 14
- 239000004475 Arginine Substances 0.000 description 11
- 229960003121 arginine Drugs 0.000 description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 11
- 239000007974 sodium acetate buffer Substances 0.000 description 11
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 6
- 238000012375 Ion exchange chromatography - high performance liquid chromatography Methods 0.000 description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 6
- 239000003513 alkali Substances 0.000 description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940074410 trehalose Drugs 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960005337 lysine hydrochloride Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2021/113273 | 2021-08-18 | ||
CN2021113273 | 2021-08-18 | ||
CNPCT/CN2022/077411 | 2022-02-23 | ||
CN2022077411 | 2022-02-23 | ||
PCT/CN2022/113202 WO2023020563A1 (fr) | 2021-08-18 | 2022-08-18 | Formulations liquides comprenant des anticorps humanisés à concentrations élevées pour le traitement de maladies liées à l'il-6 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117858722A true CN117858722A (zh) | 2024-04-09 |
Family
ID=85240061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280054611.7A Pending CN117858722A (zh) | 2021-08-18 | 2022-08-18 | 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117858722A (fr) |
WO (1) | WO2023020563A1 (fr) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
TWI505838B (zh) * | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
CR20180465A (es) * | 2016-03-07 | 2019-03-04 | Sanofi Biotechnology | Composiciones y métodos para tratar artritis reumatoide |
JP2021504482A (ja) * | 2017-11-30 | 2021-02-15 | バイオ−テラ ソリュ−ションズ,エルティーディー. | Il‐6関連疾患を治療するためのヒト化抗体の液体製剤 |
WO2022037606A1 (fr) * | 2020-08-19 | 2022-02-24 | Bio-Thera Solutions, Ltd. | Formulations liquides comprenant des anticorps humanisés à concentrations élevées pour le traitement de maladies liées à il-6 |
-
2022
- 2022-08-18 WO PCT/CN2022/113202 patent/WO2023020563A1/fr active Application Filing
- 2022-08-18 CN CN202280054611.7A patent/CN117858722A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2023020563A1 (fr) | 2023-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111110842B (zh) | 一种治疗il-6相关疾病的人源化抗体的液体制剂 | |
AU2012244764B2 (en) | Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc | |
DK2531218T3 (en) | immunoglobulin | |
CN110494164B (zh) | 一种靶向治疗TNF-α相关疾病的人抗体制剂 | |
CN111556744B (zh) | 包含vegf拮抗物的液体组合物 | |
US20220177563A1 (en) | Stable secukinumab injection and preparation method therefor | |
EP3569224A1 (fr) | Formule liquide stable | |
CN116261448A (zh) | 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂 | |
CA3129901A1 (fr) | Formulation d'anticorps therapeutique | |
CN117858722A (zh) | 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂 | |
CN113456582A (zh) | 重组人源化抗pd-1单克隆抗体的液体制剂 | |
CN112618698A (zh) | 一种人白细胞介素10-Fc融合蛋白的注射制剂 | |
CN114984207A (zh) | 一种抗pd-1纳米抗体制剂 | |
CN110302377B (zh) | 一种靶向治疗TNF-α相关疾病的人抗体制剂 | |
CN116157115A (zh) | 稳定的药物制剂 | |
KR20230032347A (ko) | 안정한 약제학적 제제 | |
WO2022217021A1 (fr) | Excipients d'amélioration de la performance et méthodes de réduction de la viscosité et d'augmentation de la stabilité de formulations biologiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |